调节细胞因子平衡与作用于T细胞的生物制剂在银屑病治疗中的研究进展

Research Progress of Biologics which can Regulate Cytokines or Affect T Cells in Psoriasis Treatment

银屑病是一种常见的慢性免疫相关性皮肤病。近20年来,随着生物制剂的出现,银屑病的治疗发生了翻天覆地的变化。T细胞及其细胞因子在银屑病的发病机制中扮演重要角色。调节细胞因子平衡的白细胞介素10及白细胞介素11,抑制T细胞活化的阿法西普及依法利珠单抗在银屑病治疗中均取得一定疗效,但阿法西普与依法利珠单抗因存在严重不良反应,均已退出市场。

Psoriasis is a common,chronic and inflammatory skin disease. The treatment of moderate-to-severe psoriasis has enormous development by adopting biologic agents in latest 20 years. T cells and their related cytokines play vital roles in the pathogenesis of psoriasis. Interleukin 10,interleukin 11,alefacept and efalizumab show good efficacy in treating moderate-to-severe psoriasis,while alefacept and efalizumab withdrew from the market because of the severe adverse reaction.